Roivant Sciences (ROIV)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$34.93+1.51%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · ROIV
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How this business ranks within health care on a research-validated quality screen. As of 2026-09-04.
The screen ranks ROIV against its sector on four durable signals: share dilution, return on capital, free-cash-flow yield, and FCF margin. Historically the highest-quality names tended toward better typical outcomes and fewer bad years over multi-year holds (strongest at three years, modest at one), and that pattern showed up even before the price moved. It characterizes business quality, not price direction.
Each leg is a sector-relative percentile (higher is better); 3 of 4 legs were available for this name. The composite is built from these four; the raw value follows each percentile for context.
A forward quality tilt, not a price prediction, and context for your own research rather than a recommendation. Not investment advice.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 53% of the time over the next year (vs 41% for the rest of the cohort, n=9986).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Complete commercial preparations and launch brepocitinib (LISRAYA) for dermatomyositis by end of September 2026, the first approved targeted therapy for this disease.
Stated as a priority in 4 of last 4 quarters. Management consistently emphasized commercial preparations and launch of brepocitinib in dermatomyositis by end of September 2026. The product received FDA approval and is commercially available as of August 28, 2026, delivering on the stated timeline.
“Commercial preparations for brepocitinib in dermatomyositis (DM) are progressing well and on track for launch by the end of September 2026”
“Commercial launch of brepocitinib in dermatomyositis (DM) is expected by the end of September 2026”
“Commercial launch of brepocitinib in dermatomyositis (DM) is expected by the end of September 2026”
“NDA was submitted to the FDA for brepocitinib in dermatomyositis (DM)”
Progress clinical development of IMVT-1402 across multiple autoimmune indications with topline data expected in second half of 2026 and registrational trials ongoing.
Stated as a priority in 4 of last 4 quarters. Management consistently reported IMVT-1402 clinical development progressing on schedule with topline data expected in second half of 2026. No revenue or income impact yet visible, reflecting ongoing development stage. Trajectory is delivering as planned.
“All clinical development timelines remain on track for IMVT-1402 across announced indications”
Improve financial performance aiming for positive net income and increased operating income through operational execution and pipeline progress.
Stated as a priority in 3 of last 4 quarters. Financials show net income improved from -$206M in 2025-Q4 to positive $303M in 2026-Q4, and operating income improved from -$285M to positive $415M over same period. This reflects delivery on the priority with a strong positive trajectory.
“Achieve positive net income and increase operating income”
Enhance cash flow from operations and sustain cash runway to support ongoing development and operations.
Stated as a priority in 3 of last 4 quarters. Cash from operating activities was negative $185.7M in 2026-Q2 and worsened to negative $270.5M in 2027-Q1, indicating challenges in cash flow improvement. However, cash and equivalents plus marketable securities remained strong at $3.9B as of June 30, 2026, supporting runway. Trajectory shows limited progress on cash flow but runway maintained.
Implement the authorized $1 billion share repurchase program funded from available cash and cash equivalents.
Stated as a priority in 2 of last 4 quarters. Management increased share repurchase authorization to $1 billion in 2026-Q1 and repurchased 7.3 million shares for $208.7 million in 2026-Q2. Execution is underway with meaningful repurchases completed, indicating delivery on the priority.
“Repurchased 7.3 million common shares for approximately $208.7 million”
Over the trailing year it converted 1.22x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
9 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated stable grew net income 46% of the time over the next year (vs 53% for the rest of the cohort, n=3872).
Not investment advice. As of 2026-09-04.
“All clinical development timelines remain on track for IMVT-1402”
“IMVT-1402 potentially registrational trial fully enrolled, topline data expected in second half of 2026”
“IMVT-1402 trial in difficult-to-treat rheumatoid arthritis ongoing with promising response rates”
“Focus on improving operating income and net income”
“Targeting improved operating income and net income”
“Improve cash from operating activities and maintain cash runway”
“Focus on cash flow improvement and runway maintenance”
“Maintain cash runway into profitability”
“Board authorized increase in share repurchase program to $1 billion”